{"id":"etn-alone","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions"},{"rate":"29","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"2-3","effect":"Serious infections (including tuberculosis)"},{"rate":null,"effect":"Demyelinating disease"},{"rate":null,"effect":"Congestive heart failure exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ETN acts as a soluble TNF receptor that competitively inhibits TNF-α from engaging membrane-bound TNF receptors on immune and inflammatory cells. By sequestering TNF-α, it suppresses the inflammatory cascade and reduces production of downstream inflammatory mediators, thereby dampening pathological immune responses in autoimmune and inflammatory conditions.","oneSentence":"ETN (etanercept) is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:00.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Plaque psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05277948","phase":"NA","title":"Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR)","status":"COMPLETED","sponsor":"Dongmei Huang","startDate":"2021-10-18","conditions":"Diminished Ovarian Reserve","enrollment":240},{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05891600","phase":"","title":"A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-06-06","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02030613","phase":"NA","title":"Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-10-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":126},{"nctId":"NCT03792841","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-02-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":212},{"nctId":"NCT06392074","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2024-03-07","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT07184853","phase":"NA","title":"Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"Graft vs Host Disease","enrollment":122},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT04973566","phase":"PHASE1","title":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT03728478","phase":"PHASE3","title":"STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS","status":"RECRUITING","sponsor":"Istituto Giannina Gaslini","startDate":"2019-05-29","conditions":"Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative","enrollment":260},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05281614","phase":"EARLY_PHASE1","title":"Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D","status":"COMPLETED","sponsor":"Benaroya Research Institute","startDate":"2022-09-21","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT00393471","phase":"PHASE3","title":"Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Active Rheumatoid Arthritis","enrollment":615},{"nctId":"NCT02471144","phase":"PHASE3","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-29","conditions":"Chronic Severe Plaque-type Psoriasis","enrollment":162},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT05379049","phase":"","title":"Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.","status":"UNKNOWN","sponsor":"University of Sulaimani","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Ankylosing Spondylitis","enrollment":80},{"nctId":"NCT02075697","phase":"","title":"Spanish Registry of Systemic Treatments in Psoriasis","status":"UNKNOWN","sponsor":"Fundación Academia Española de Dermatología","startDate":"2008-10","conditions":"Psoriasis","enrollment":3500},{"nctId":"NCT04981171","phase":"NA","title":"Electro-thumbtack Needle Therapy for Chronic Neck Pain","status":"UNKNOWN","sponsor":"Shi Hangyu","startDate":"2022-04-03","conditions":"Neck Pain","enrollment":180},{"nctId":"NCT03073200","phase":"PHASE3","title":"Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-03-28","conditions":"Plaque Psoriasis","enrollment":201},{"nctId":"NCT01602302","phase":"PHASE4","title":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT00833729","phase":"PHASE4","title":"The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab","status":"COMPLETED","sponsor":"Dermatrials Research","startDate":"2009-02","conditions":"Plaque Psoriasis","enrollment":10},{"nctId":"NCT01971346","phase":"PHASE4","title":"The Immunological Basis for Treatment Resistance to Anti-TNF Treatments","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2014-03-13","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT00346294","phase":"PHASE4","title":"An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":115},{"nctId":"NCT01303874","phase":"PHASE4","title":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis","enrollment":112},{"nctId":"NCT04077957","phase":"PHASE4","title":"Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-07","conditions":"Ankylosing Spondylitis, Spondyloarthritis","enrollment":100},{"nctId":"NCT02433184","phase":"PHASE4","title":"Very Early Versus Delayed Etanercept in Patients With RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-07","conditions":"Rheumatoid Arthritis","enrollment":120},{"nctId":"NCT03781375","phase":"PHASE3","title":"Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Amgen","startDate":"2000-08-24","conditions":"Juvenile Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT02986139","phase":"PHASE3","title":"Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-11-29","conditions":"Arthritis, Rheumatoid; Arthritis, Psoriatic","enrollment":111},{"nctId":"NCT01865552","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2013-05","conditions":"Healthy","enrollment":138},{"nctId":"NCT02656082","phase":"PHASE2","title":"Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2016-02-01","conditions":"Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous","enrollment":25},{"nctId":"NCT03273088","phase":"PHASE1","title":"Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-12-04","conditions":"Phase 1, Bioequivalence","enrollment":34},{"nctId":"NCT01875991","phase":"PHASE4","title":"Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-05","conditions":"Rheumatoid Arthritis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01901185","phase":"PHASE3","title":"Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06-11","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":77},{"nctId":"NCT01934933","phase":"PHASE4","title":"Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-09-24","conditions":"Ankylosing Spondylitis","enrollment":150},{"nctId":"NCT01927757","phase":"PHASE4","title":"Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-05-06","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT03403140","phase":"PHASE3","title":"Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )","status":"UNKNOWN","sponsor":"Gema Biotech S.A.","startDate":"2016-10-06","conditions":"Rheumatoid Arthritis","enrollment":141},{"nctId":"NCT00201838","phase":"PHASE1, PHASE2","title":"Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2001-07","conditions":"Pancreatic Neoplasms, Adenocarcinoma","enrollment":38},{"nctId":"NCT02330380","phase":"","title":"Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2013-04","conditions":"Psoriasis, Inflammation","enrollment":26},{"nctId":"NCT03193957","phase":"PHASE2","title":"An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2017-05-15","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT03193203","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2017-03-24","conditions":"Healthy","enrollment":50},{"nctId":"NCT01294397","phase":"PHASE1","title":"Effects of Denosumab on the Pharmacokinetics of Etanercept","status":"TERMINATED","sponsor":"Amgen","startDate":"2011-03","conditions":"Postmenopausal, Osteopenia, Rheumatoid Arthritis","enrollment":19},{"nctId":"NCT02378506","phase":"PHASE3","title":"Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-04","conditions":"Arthritis, Rheumatoid","enrollment":188},{"nctId":"NCT01230177","phase":"","title":"Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Arthritis, Rheumatoid","enrollment":3},{"nctId":"NCT02274792","phase":"PHASE4","title":"Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":132},{"nctId":"NCT02999776","phase":"PHASE1","title":"Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis","status":"UNKNOWN","sponsor":"Pantec Biosolutions AG","startDate":"2016-11","conditions":"Psoriatic Plaque","enrollment":30},{"nctId":"NCT01894412","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2013-07","conditions":"Healthy","enrollment":48},{"nctId":"NCT01578850","phase":"PHASE4","title":"Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07","conditions":"Rheumatoid Arthritis","enrollment":491},{"nctId":"NCT02799498","phase":"PHASE1","title":"Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-10","conditions":"Healthy Men and Women","enrollment":36},{"nctId":"NCT01716637","phase":"PHASE1","title":"Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Life Extension Foundation Inc.","startDate":"2010-02","conditions":"Alzheimer's Disease","enrollment":12},{"nctId":"NCT00141726","phase":"PHASE2","title":"Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2003-10","conditions":"Lung Injury, Acute, Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans","enrollment":34},{"nctId":"NCT02588534","phase":"PHASE1","title":"Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08","conditions":"Healthy Men and Women","enrollment":36},{"nctId":"NCT00688103","phase":"PHASE4","title":"Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan","status":"COMPLETED","sponsor":"Japan Biological Agent Study Integrated Consortium","startDate":"2005-06","conditions":"Rheumatoid Arthritis","enrollment":151},{"nctId":"NCT01490047","phase":"PHASE1","title":"Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas","status":"WITHDRAWN","sponsor":"Ludwig Institute for Cancer Research","startDate":"2013-01","conditions":"Solid Tumors, Lymphomas","enrollment":""},{"nctId":"NCT01282294","phase":"","title":"Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures","status":"COMPLETED","sponsor":"Synthes GmbH","startDate":"2011-02","conditions":"Tibia Fractures","enrollment":100},{"nctId":"NCT00156247","phase":"PHASE2","title":"Acitretin and Etanercept in Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-09","conditions":"Psoriasis","enrollment":10},{"nctId":"NCT01725620","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2012-11","conditions":"Healthy","enrollment":48},{"nctId":"NCT00729131","phase":"","title":"Functional Implications of TNF","status":"COMPLETED","sponsor":"National Institute of Environmental Health Sciences (NIEHS)","startDate":"2008-08","conditions":"Bronchitis","enrollment":10},{"nctId":"NCT00654368","phase":"PHASE4","title":"CAMEO: Canadian Methotrexate and Etanercept Outcome Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-06","conditions":"Rheumatoid Arthritis","enrollment":258},{"nctId":"NCT01044836","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2010-01","conditions":"Healthy","enrollment":42},{"nctId":"NCT01431404","phase":"PHASE1","title":"Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects","status":"COMPLETED","sponsor":"Hanwha Chemical","startDate":"2011-08","conditions":"Healthy","enrollment":44},{"nctId":"NCT00110981","phase":"PHASE4","title":"Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":"Psoriasis","enrollment":86},{"nctId":"NCT00078793","phase":"","title":"Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2000-06","conditions":"Juvenile Rheumatoid Arthritis","enrollment":600},{"nctId":"NCT00800982","phase":"NA","title":"Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-10","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT00244556","phase":"PHASE4","title":"Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT00195494","phase":"PHASE4","title":"Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-11","conditions":"Rheumatoid Arthritis","enrollment":542},{"nctId":"NCT01657513","phase":"NA","title":"TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis","status":"UNKNOWN","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2012-06","conditions":"Psoriasis","enrollment":60},{"nctId":"NCT00285233","phase":"PHASE1, PHASE2","title":"Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2000-09","conditions":"Type 1 Diabetes, Hypoglycemia","enrollment":8},{"nctId":"NCT01635686","phase":"PHASE1","title":"Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":38},{"nctId":"NCT00936065","phase":"PHASE4","title":"Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Moderate to Severe Psoriasis","enrollment":60},{"nctId":"NCT01145950","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2010-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT00931957","phase":"NA","title":"Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2010-10","conditions":"Behcet Syndrome, Uveal Disease","enrollment":80},{"nctId":"NCT00099554","phase":"PHASE4","title":"Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-05","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT00161655","phase":"PHASE4","title":"Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-04","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":60},{"nctId":"NCT00705042","phase":"PHASE1","title":"Study Evaluating Enbrel Drug Levels in Healthy Male Chinese Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-07","conditions":"Healthy Subjects","enrollment":60},{"nctId":"NCT00764725","phase":"PHASE4","title":"Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2002-12","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT00678782","phase":"PHASE2","title":"Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis","status":"COMPLETED","sponsor":"University of Padova","startDate":"2005-04","conditions":"Persistent Knee Joint Synovitis","enrollment":31},{"nctId":"NCT00502879","phase":"PHASE1","title":"Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-07","conditions":"Healthy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["etanercept"],"phase":"marketed","status":"active","brandName":"ETN Alone","genericName":"ETN Alone","companyName":"Japan Biological Agent Study Integrated Consortium","companyId":"japan-biological-agent-study-integrated-consortium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ETN (etanercept) is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}